A spectacular demand
Where does this shortage come from? As mentioned “ West France “, tensions over paracetamol stocks have been going on for several months already, according to Sanofi. The laboratory faces an unprecedented increase in demand since the start of the pandemic. The health crisis (in particular the resurgence of the epidemic linked to Omicron) and seasonal illnesses (flu, headaches) have prompted consumers to stock up on paracetamol, and therefore Doliprane.
As a reminder, this drug is prescribed in case of diagnosis of Covid-19. The High Council of Public Health quickly recommended it during the pandemic. In 2021, sales of its pain relief products increased by 7.2%, to reach 1.1 billion euros. Faced with such a rushSanofi has not kept pace.
A shortage until the summer
Still according to “La Dépêche du Midi”, orders should be limited to a maximum of 720 units per pharmacy. The return to normal is scheduled for June 2022.
